Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus Pemetrexed in Advanced Non-Squamous NSCLC
NCT00806819Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2008
- Primary completion
- Jun 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 32
01
Overview
A Phase 3 trial of nintedanib intravenous solution in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Dec 2008; status: completed.
02
Drugs
nintedanib intravenous solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00806819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806819.